Navigation Links
Brazil's biotech firms: From imitators to innovators in health-related products
Date:6/6/2008

  • several monoclonal antibodies for cancer treatment (Recepta Biopharma, of So Paulo);
  • a recombinant protein for treating melanoma as well as anti-hypertensive and an analgesic peptide both isolated from snake venom (COINFAR, of So Paulo); and
  • fetal, neonatal and adult stem cell therapies for cardiac disease, type I diabetes and neonatal hypoxia (Cryopraxis, Rio de Janeiro).

Barriers to development

Major challenges include:

  • A patent regime in desperate need of reform

    The Brazilian patent office can take over seven years to process patent applications for drug candidates. Brazilian law prohibits patenting some important biotechnologies, such as recombinant versions of proteins found in nature. Some companies are also concerned that once a pharmaceutical product has been approved by the patent office, ANVISA (the national regulatory agency that approves health products, among other activities) can withhold approval on grounds such as eventual public access issues.

  • Regulatory issues

    The main regulatory roadblock highlighted by both public and private sector interviewees is the lack of practical experience in product development and manufacturing on the part of ANVISA regulators. Other commonly cited stumbling blocks include long delays in the ethics approval process for clinical trials as well as biosafety and biodiversity regulations.

  • Human resources

    Although Brazil has been successful in raising the overall level of biotech expertise, there is evidence of a disconnect between the output of existing training programs and the actual needs of the health biotech sector. Lack of sufficiently specialized and targeted training programs and the "academic model" of university preparation are limiting the supply of appropriately-trained personnel. An additional challenge for private industry, especially SMEs, is their inability to match or exceed the incen
    '/>"/>


Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
Program on Life Sciences, Ethics and Policy,McLaughlin-Rotman Centre for Global Health
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... -- New interactive learning forums will ... of the medical device industry at the 2013 ... from June 18-20 in Philadelphia ... ) , These all-new MedTech Innovate ... presentations and implementable solutions on the most cutting-edge ...
(Date:5/17/2013)... BEIJING , May 17, 2013  Yongye International, ... "Company"), a leading developer, manufacturer, and distributor of crop ... China , today announced that, on May 16, ... board of directors (the "Board of Directors") was provided ... ( Hong Kong ) Limited ("Abax") to ...
(Date:5/17/2013)... Health, Inc., a company developing natural compounds to address ... is today reporting top-line results from a Phase Ib ... drug-resistant epilepsy.  The data are being presented at the ... Dr. Steven Schachter , Harvard Medical ... In this study, INS001 appeared safe and well tolerated. ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... LUND, Sweden, January 18 ,ThromboGenics NV (Euronext ... (Nordic Exchange: BINV) announce today that they,have ... Denmark to,initiate a Phase I clinical trial ... a monoclonal antibody that targets the angiogenic ...
... CLAREMONT, Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... annual,management meetings including yearend business review, planning ... commenced in,Xiaotangshan, Beijing on January 11, 2008., ... staff from Kiwa,s corporate,headquarters in Beijing, and ...
... Types Broadens Project Coalition with Addition of ... Misys Healthcare, CHICAGO, Jan. 17 The HL7 ... starts 2008 on a strong,note adding four new benefactors ... Systems joined in the fall of 2007,ImageTek, Inc. in ...
Cached Biology Technology:ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 2ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 3ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 4ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 5Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3New Benefactors Show Support for CDA4CDT: 2New Benefactors Show Support for CDA4CDT: 3New Benefactors Show Support for CDA4CDT: 4New Benefactors Show Support for CDA4CDT: 5New Benefactors Show Support for CDA4CDT: 6New Benefactors Show Support for CDA4CDT: 7
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
(Date:5/17/2013)... Why Tibetan antelope can live at elevations of ... research published in Nature Communications , investigators ... evidence that some genetic factors may be associated ... The data in this work will also provide ... biology of other ruminant species. , The Tibetan ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2New X-ray method shows how frog embryos could help thwart disease 2
... scientist, explorer and conservationist, will receive the Academy of ... He is the first Australian to receive the award ... leading thinkers and writers, Flannery has discovered more than ... has published more than 130 peer-reviewed scientific papers and ...
... that a certain class of RNA (known as long non-protein-coding ... infection. These findings, published today in the online journal ... at the body,s response to viral infection. "To our ... technology to clearly demonstrate that lncRNAs are involved in the ...
... Ohio New research links three molecules to a critical ... myeloma, a presently incurable cancer of the blood. , The ... and other blood cancers, according to researchers at The Ohio ... Richard J. Solove Research Institute (OSUCCC James) who led ...
Cached Biology News:Scientist Tim Flannery is first Austrailian to receive Joseph Leidy Award 2A new player in the innate immunity game? 2Study identifies key molecules in multiple myeloma 2
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: